CJC-1295 DAC: limits of adverse-reaction evidence
Teichman and colleagues’ abstract describes subcutaneous CJC-1295 in healthy adults across two trials lasting 28 and 49 days. No serious adverse reactions were reported. [1]
That does not mean no adverse reactions occurred. The abstract does not establish equivalence to a particular DAC/no-DAC product or batch, or long-term human safety. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Serious adverse reactions | Healthy adults, subcutaneous administration, two trials lasting 28 and 49 days | None were reported; that does not mean no adverse reactions occurred, and the abstract does not establish long-term safety | [1] |
References
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults https://doi.org/10.1210/jc.2005-1536.